title: Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety.
abstract: Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent clinical antitumor effects in a variety of blood cancers. However, clinical activity in solid tumors has been disappointing and toxicity has been a serious concern (Lamers et al., 2013; Morgan et al., 2010). We recently found that a CAR composed of a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical models of blood cancer and adenocarcinoma (Posey et al., 2016).
authors.affiliation: Center for Cellular Immunotherapies and Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, PA, 19104-5156 USA. Electronic address: aposey@mail.med.upenn.edu.
authors.forename: Avery D
authors.initials: AD
authors.lastname: Posey
authors.affiliation: Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark.
authors.forename: Henrik
authors.initials: H
authors.lastname: Clausen
authors.affiliation: Center for Cellular Immunotherapies and Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, PA, 19104-5156 USA. Electronic address: cjune@exchange.upenn.edu.
authors.forename: Carl H
authors.initials: CH
authors.lastname: June
mesh_terms: D000230:Adenocarcinoma; D006801:Humans; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell